Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Sangivamycin is a nucleoside analog.1 It incorporates into severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and reduces the number of plaque-forming units (PFUs) in SARS-CoV-2-infected Vero E6 cells when used at a concentration of 72 nM. Sangivamycin (0.3 µM) induces cell cycle arrest at the G2/M phase and apoptosis in MCF-7/adr cells, effects that can be prevented by the JNK inhibitor SP600125 (Item No. 10010466) or protein kinase Cδ (PKCδ) inhibitor rottlerin (Item No. 12006).2
WARNING This product is not for human or veterinary use.
1. Sangivamycin is preferentially incorporated into viral RNA by the SARS-
2. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-